🇺🇸 FDA
Pipeline program

MRx0029

INNOVATE-LBP 1.0

Phase 1 mab terminated

Quick answer

MRx0029 for Idiopathic Parkinson Disease is a Phase 1 program (mab) at 4D Molecular Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
4D Molecular Therapeutics
Indication
Idiopathic Parkinson Disease
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials